Q 122

Drug Profile

Q 122

Alternative Names: MSX-122; Q122

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Emory University; University of Queensland
  • Developer Altiris Therapeutics; QUE Oncology
  • Class Anti-inflammatories; Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Hot flashes

Highest Development Phases

  • No development reported Hot flashes
  • Discontinued Solid tumours

Most Recent Events

  • 28 Dec 2017 No recent reports of development identified for phase-I development in Hot-flashes in USA (PO)
  • 08 Nov 2017 QUE Oncology plans a clinical trial for Vasomotor symptoms (In volunteers) in Australia in November 2017 (ACTRN12617001542381p)
  • 03 Nov 2014 Phase-I clinical trials in Hot flashes in USA (PO) before November 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top